NCT03911466 - Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2020

Primary Completion Date

November 6, 2024

Study Completion Date

November 6, 2024

Conditions

Opioid-Related DisordersDrug AddictionPregnancy RelatedSubstance AbuseDrug AbuseNeonatal Abstinence SyndromeNeonatal Opioid Withdrawal SyndromeDrug Abuse in Pregnancy

Interventions

DRUG

Buprenorphine Injection

Weekly and monthly formulations of injectable, extended-release buprenorphine (BUP-XR).

DRUG

Buprenorphine Sublingual Product

Sublingual buprenorphine (BUP-SL), administered daily.

Trial Locations (12)

15213

Pregnancy Recovery Center at Magee-Womens Hospital of UPMC, Pittsburgh

25701

Marshall Health MARC Program, Huntington

29425

Medical University of South Carolina, Charleston

32204

Gateway Community Services, Jacksonville

37232

Vanderbilt University Medical Center, Nashville

45229

University of Cincinnati Health Perinatal Addictions Program, Cincinnati

84108

University of Utah SUPeRAD Clinic, Salt Lake City

87106

University of New Mexico Milagro Clinic, Albuquerque

97214

CODA, Inc., Portland

98107

Addiction Recovery Services (ARS), Swedish Medical Center, Seattle

02114

Massachusetts General Hospital HOPE Clinic, Boston

02118

Boston Medical Center, Boston

All Listed Sponsors

collaborator

National Institute on Drug Abuse (NIDA)

NIH

collaborator

The Emmes Company, LLC

INDUSTRY

lead

T. John Winhusen, PhD

OTHER